A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of human patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of human patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.